Viz.ai’s intelligent care coordination system connects multidisciplinary care teams earlier, coordinates care, and puts patients first with the company’s software suite, which has been clinically proven to synchronize stroke care, decrease time to treatment, and greatly improve patient outcomes.

Viz.ai’s flagship solution, Viz LVO, uses AI to automatically detect suspected large vessel occlusion (LVO) strokes on computed tomography angiography imaging and directly alert on-call stroke specialists about potentially treatable patients in a standalone or multi-hospital network.

“Minutes matter when you’re having a stroke, which is why Viz.ai is dedicated to reducing time to treatment and improving patient outcomes through improved care coordination,” said Chris Mansi, co-founder, and CEO of Viz.ai. “The CE Mark allows us to bring our leading AI software to the EU, significantly expanding the number of patients we can help get access to life-saving therapy.”

Viz.ai has had its fair share of accomplishments. The company has raised $150 million since its inception. It won De Novo clearance for Viz LVO. Viz.ai announced its second FDA clearance for Viz CTP through the 510(k) pathway, offering healthcare providers an important tool for automated cerebral perfusion image analysis.

A third FDA clearance was granted in 2020 for Viz ICH, which uses AI to automatically detect suspected intracranial hemorrhage on CT imaging. In 2020, CMS granted Viz.ai the first New Technology Add-on Payment (NTAP) for artificial intelligence software for Viz LVO.

In 2018, MD+DI named Viz.ai as one of six AI companies set to rock the medtech world.